Zhang et al. showed that PLGA nanoparticles containing Rapamycin and blood clotting factor FVIII were much more effective than exogenous FVIII in Hemophilia A therapy (where lack of FVIII results in a bleeding disorder) [73] (Table 1). Here, F8 is linked to hemophilia A.